PML patients who survived more than a year after onset appeared 4.8 times more likely to exhibit a discernable CD4+ T cell response compared to PML patients who passed away within a year of onset—an unsurprising observation considering the interplay between CD4+ and CD8+ T cells [276]. The gene discussed is CD8A; the disease is progressive multifocal leukoencephalopathy.